Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00644488 | A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer | PHASE1 | COMPLETED | 7 | — | — | Jul 1, 2008 | Mar 1, 2009 | Jan 25, 2011 | 3 | Japan |
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | Active |
| Name | Type | Description |
|---|---|---|
| BMS-641988 (AR#2) | DRUG | Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks |
Inclusion Criteria: * Patients with castration-resistant prostate cancer and serum testosterone ≤50 ng/dL progressive to current therapy who satisfy the inclusion and exclusion criteria